Abstract: The disclosure is generally related to therapeutic compositions and methods for use in the treatment of somatosensory conditions, including pain and pruritis. In some aspects, the compositions comprise (i) a nonsteroidal anti-inflammatory drug (NSAID), an opioid, or a combination thereof, and (ii) one or more transdermal delivery agents. In some aspects, the compositions comprise (i) an antihistamine, a kappa opioid receptor agonist, an anti-pruritogen, or a combination thereof, and (ii) one or more transdermal delivery agents.

Abstract: The disclosure is generally related to therapeutic compositions and methods for use in the treatment of somatosensory conditions, including pain and pruritis. In some aspects, the compositions comprise hyaluronic acid having a therapeutically effective molecular weight and one or more transdermal delivery agents.

Abstract: A decorative eyelet ring for customizing an existing eyelet in an article of clothing is described. The decorative eyelet ring comprises a ring element formed to be positionable around an existing eyelet of an article of clothing. A clasp portion extends from the ring element and comprises a set of support elements that extend distally from the ring element. The set of support elements is formed to be insertable into the existing eyelet. Each support element has a first end and a second end. The first end of each support element is connected with the ring element, and a tab extends perpendicularly from the second end of each support element for securing the decorative eyelet ring to the existing eyelet.

Abstract: The present invention provides methods, compositions, and kits useful for reducing pain in a subject by inhibiting Epac, PLC?, and/or PLD. In addition, the invention provides a variety of prescreening and screening methods aimed at identifying agents that reduce pain. Methods of the invention can involve assaying test agent binding to Epac, PLC?, or PLD. Alternatively, test agents can be screened for their ability to alter the level of Epac, PLC?, or PLD polypeptides, polynucleotides, or action.

Abstract: Pain, for example, neuropathic pain such as peripheral neuropathic pain, may be treated or alleviated by administering to a subject an effective amount of one or more caspase inhibitors. Activator and effector caspases, defining components of programmed cell death (PCD, apoptosis) signaling pathways, have been found to also contribute to pain-related behavior in animals with small-fiber peripheral neuropathies. The death receptor ligand, tumor necrosis factor alpha (TNF?) and its downstream second messenger, ceramide, also produce pain-related behavior via this mechanism.